The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, placebo-controlled study about the effect of
metformin in patients with mild Graves' ophthalmopathy. Eighty patients with mild
ophthalmopathy will be included. Each patient will be given either metformin (500mg PO three
times a day) or placebo ( PO three times a day ) for 6 months and then followed for 6 months
after withdrawal of treatment.